



Tampa, Florida, United States – October 30, 2023 - CTT Pharmaceutical Holdings, Inc. (OTC:CTTH) received approval to submit our patented dissolvable strips for a US Government contract. If approved CTT Pharma will receive the necessary capital to create prototypes and also have the potential for further funding via the government for research and ultimately development of our technology. CTT will not have to issue shares for any funding from the government. CTT filed our proposal to the government in Q3 and anticipate getting a response in Q4. CTT Pharma believes there's a real need for our technology in many sectors but believes that nicotine presents the greatest need as 480,000 Americans die annually or approximately 1,300 daily from smoking, additionally there is 16 million Americans that are living with a disease caused by smoking, per the CDC.

There are currently no fast dissolvable oral nicotine products, as the market currently offers nicotine gum, nicotine lozenges and nicotine pouches. CTT's patented dissolvable strips would enter the bloodstream once dissolved in the mouth, bypassing the lungs and digestive tract, allowing for better absorption, faster onset, and the ability to combine actives. This technology can be used for many industries including but not limited to Pharmaceuticals, Nicotine, and Vitamins. Furthermore, CTT believes it can create a smoke-free product with less milligrams on a strip than traditional oral delivery methods because of higher bioavailability and absorption.

Ryan Khouri, CEO of CTT Pharma stated, "As a former smoker and someone who has lost loved ones to smoking I believe we have a responsibility to consumers to give them more smokeless options, better technology and something that doesn't stay in the mouth for an extended period of time. I'd like nicotine usage to evolve to the point that when people decide to stop at any point in their life, they will be able to move forward without the health issues that come from smoking or vaping. I'm optimistic that can be achieved, but funding to innovative companies like CTT Pharma is a must to help create new products."

CTT will update shareholders as more information becomes available.

CTT Pharma – 813-606-0060

